Canadian certificates of supplementary protection issued

Certificates of supplementary protection (CSPs) are used as an extension of intellectual property rights, compensating pharmaceutical companies for the time between invention of a product and it entering the market. In effect, they extend the patent by a number of years. Health Canada announced three CSPs in June 2018:

  1. neisseria meningitidis grp B recombinant lipoprotein 2086 sub-family A/neisseria meningitidis group B recombinant lipoprotein 2086 sub-family B (Pfizer’s Trumenba);
  2. letermovir (Merck’s Prevymis);
  3. guselkumab (Tremfya)

These three products join a further four CSPs, with decisions pending on eight others.

Health Canada also made changes to their CSP application system, increasing their fees to C$9,192.

Tagged with

Published 29. June 2018 in News, News Canada